8/105 sources · 4 publishersUpdated Oct 8, 15:03 UTC
Sagimet completes underwritten equity and warrant financing
Sagimet Biosciences completed its underwritten sale of Series A common stock and pre-funded warrants on October 1. The company said the financing will support a Phase 3 acne study and launch preparation for denifanstat, development of TVB-3567 through Phase 2 results, its topical FASN inhibitor program, and general operations. Commodore Capital led the financing alongside new and existing institutional investors.
Why it matters
The transaction adds capital for Sagimet's clinical and pre-commercial programs. It also increases the potential share count through the newly sold equity and immediately exercisable pre-funded warrants.
Key facts
- 1Sagimet said it completed the underwritten offering on October 1, 2026. globenewswire.com
- 2The company reported gross proceeds of approximately $115.0 million before underwriting discounts, commissions and offering costs. globenewswire.com
- 3Sagimet said the pre-funded warrants can be exercised immediately at $0.0001 for each share. investing.com
- 4Sagimet plans to combine the net proceeds with its existing cash, cash equivalents and marketable securities for drug development and corporate purposes. globenewswire.com
- 5Commodore Capital led the financing, with participation from several institutional investors. globenewswire.com
Open questions
- Materials describe the common-stock issuance as either 8.75M shares or 8,750,010 shares.
- Materials describe the warrant coverage as either 2.75M shares or 2,750,010 shares.
- Materials variously state proceeds as $115M and approximately $115.0 million, reflecting rounding differences.
Summary written by AlphAI from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.